ArticleJournal of inflammation research2024
Rheumatoid Factor Titer as an Indicator of the Risk of Rheumatoid Arthritis Activity: Dose-Effect Analysis with the Restricted Cubic Spline Model.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Subcutaneous methotrexate compared with oral methotrexate in rheumatoid arthritis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers.Annals of medicine and surgery (2012) · 2025Article
- High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA.Pediatric rheumatology online journal · 2025Article
- Outdoor light spending time, genetic predisposition and incident Parkinson's disease: the mediating effect of lifestyle and vitamin D.Journal of health, population, and nutrition · 2025Article
- Mediating Role of Lipid Accumulation Products (LAP) in the Association of WBC with MASLD: SWH 2021-2023.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid factor (RF) titer is known to be correlated to rheumatoid arthritis (RA) activity, but the ideal cut-off titer of RF remains unclear. Here, the relationship between RF titer and RA activity was investigated in order to determine the ideal RF value indicative of the risk of RA activity. Methods: Clinical data from 2044 eligible patients were collected from the First Affiliated Hospital of Anhui Medical University from February 2022 to October 2023. A restricted cubic spline (RCS) model was used to evaluate the relationship between RF titer and RA activity. Results: Data from a total of 2044 patients with RA were collected and analyzed. Multivariate logistic regression analysis revealed that higher RF levels were significant predictors of the risk of RA activity calculated according to the disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) (OR = 2.020, 95% CI = 1.457-2.801, P < 0.001) and DAS28-C reactive protein (CRP) (OR = 1.526, 95% CI = 1.092-2.131, P = 0.013), after the results were adjusted for potential covariates. The relationship between log2RF and the risk of RA activity was non‑linear in the RCS model (P < 0.05). The cutoff value of RF titers for determining the risk of RA activity was 65.80 IU/mL. When RF exceeded the cutoff value, the risk of RA activity based on DAS28-ESR increased by 99.2% and the risk of RA activity based on DAS28-CRP increased by 62.8% (P < 0.001). Conclusion: The risk of RA activity increased non-linearly with the continuous change in RF titer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.